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Several studies indicate that dermal fibroblasts have a
specific role in the pathophysiology of psoriasis. We have
previously found that cultured fibroblasts from psoriatic
patients are hyperproliferative and have low cyclic AMP-
dependent protein kinase activity. In this study, we
observed that these cells are also larger than normal.
Given the key role of mitogen-activated protein kinases
(MAPK) in the regulation of cell proliferation and cyto-
skeleton function, we characterized MAPK in psoriatic
fibroblasts and in normal fibroblasts. Serum and platelet-
derived growth factor treatment of serum-deprived
fibroblasts led to a larger increase in MAPK activity in
psoriatic cells than in normal cells. We then purified
MAPK by ion-exchange chromatography. MAPK activity
was again found to be significantly higher in psoriatic
Mitogen-activated protein kinases [MAPK, alsoknown as Erks (extracellular signal-regulated kin-ases)] are key intermediates in the transduction ofextracellular signals to the nucleus (Brunet et al,1994; Graves et al, 1995; Seger and Krebs, 1995), and
therefore in the regulation of cell proliferation. The best characterized
mammalian examples of these kinases are Erk1 (also called p44mapk)
and Erk2 (p42mapk), initially identified by Ray and Sturgill (1987).
Erk1 and Erk2 are proline-directed serine/threonine protein kinases
and are ubiquitously expressed.
On binding of a soluble factor (e.g., growth factors) to its specific
cell surface receptor, the MAPK pathway is activated as follows.
Activated and autophosphorylated receptor tyrosine kinases recruit
adaptor proteins, e.g., Grb2. Grb2 interacts with a guanine exchange
protein, Sos, and thereby activates Ras (Seger and Krebs, 1995). Thus,
inactive GDP-bound Ras is converted to the GTP-binding form; this
active form targets Raf to the plasma membrane, where it is activated
(Leevers et al, 1994). In turn, activated Raf phosphorylates and activates
MEK (MAPK/Erk-activating kinase), a specific MAPK activator
(Crews et al, 1992). MEK is a threonine/tyrosine protein kinase that
phosphorylates the Thr*-Glu-Tyr* motif in MAPK subdomain VIII.
Interestingly, activated MAPK is the only factor that translocates into
the nucleus during this cascade (Chen et al, 1992; Lenormand et al,
1993). In the nucleus, MAPK phosphorylates transcriptional factors
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fibroblasts than in normal cells, both when deprived of
serum (p , 0.01) and when stimulated with serum
(p , 0.05). Interestingly, 8-bromo-cAMP treatment
inhibited serum-stimulated MAPK phosphorylation in
normal fibroblasts but had no effect in psoriatic
fibroblasts. We observed a temporal variation in nuclear
localization of phosphorylated MAPK in cultured
fibroblasts stimulated by either serum or platelet-derived
growth factor. No difference in the localization of phos-
phorylated MAPK in normal and psoriatic skins was
found. Psoriatic fibroblasts are the first example of a
MAPK pathway abnormality in large human benign
hyperproliferative cells. Key words: cyclic AMP-dependent
protein kinase/mitogen-activated protein kinases/psoriasis.
J Invest Dermatol 110:872–879, 1998
such as Elk-1 involved in c-fos promoter activation (Gille et al, 1995)
and c-myc (Pelech and Sanghera, 1992). There are also MAPK substrates
in the cytoplasm, and they include cytoskeleton proteins (Seger and
Krebs, 1995). MAPK is not only activated in the G0/G1 transition,
but also has two phases of activation during the cell cycle: during the
G1 and the G2/M phases (Tamemoto et al, 1992).
MAPK activity is modulated by numerous factors, particularly
growth factors and cytokines, including epidermal growth factor (Buday
and Downward, 1993), nerve growth factor (Gomez and Cohen,
1991), platelet-derived growth factor (PDGF), insulin (de Vries-Smits
et al, 1992), and interleukin 1 (Bird et al, 1991). Other soluble factors,
including muscarinic agonists like α-thrombin, acetylcholine (Johnson
et al, 1994), and α- and β-adrenergic agonists (Bogoyevitch et al,
1996), stimulate the cascade by binding to receptors coupled to
heterotrimeric G proteins (Sugden and Clerk, 1997). Erks appear to
be strongly activated by phorbol esters, e.g., 12-O-tetradecanoylphorbol
13-acetate, as protein kinase C (PKC) positively regulates the MAPK
pathway through both Ras-dependent and Ras-independent mechan-
isms (Burgering et al, 1993a). Heat shock (Dubois and Bensaude, 1993),
mechanical changes (Sadoshima and Izumo, 1993), and variations in
extracellular Ca21 also activate the MAPK pathway (Huang et al, 1995).
MAPK activation in response to a stimulating signal is transient,
suggesting that there is one or more mechanisms inactivating these
kinases. MAPK can be deactivated by the action of either phosphatase
2A, which is a phosphoserine and phosphothreonine specific protein
phosphatase, or CD45, a phosphotyrosine specific protein phosphatase
(Anderson et al, 1990). Several dual specificity phosphatases deactivate
MAPK by dephosphorylating tyrosine and threonine residues (for
review see Zolnierowicz and Hemmings, 1996). cAMP may be
involved in the negative regulation of the MAPK pathway in several
cell types, including fibroblasts (Burgering et al, 1993b; Cook and
McCormick, 1993; Hordijk et al, 1994). Presumably cAMP-dependent
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protein kinase A (PKA) mediate this effect, as no inhibition was
observed in cells expressing a mutant regulatory subunit of PKA
(Sevetson et al, 1993). Raf-1 is phosphorylated by PKA at a consensus
site within the Raf-1 regulatory domain. This diminishes Raf-1
affinity for Ras and explains the inhibition of Raf-1 activation and,
consequently, that of the MAPK cascade downstream from Raf-1 (Wu
et al, 1993). Moreover, PKA is able to phosphorylate the active domain
of Raf-1, which would inhibit Raf-1 activity (Hafner et al, 1994).
There seems to be synergy, however, between cAMP and the MAPK
pathway effect in some cells; e.g., in PC12 pheochromocytoma cells,
nerve growth factor and cAMP have a synergistic effect on neurite
formation (Gunning et al, 1981). Similarly, McKenzie and Pouysse´gur
(1996) showed that PKA-mediated growth inhibition is independent
of the MAPK pathway in rat fibroblasts, PKA simply delaying MAPK
activation by mitogens.
MAPK in human dermal fibroblasts is activated by each PDGF AA,
PDGF BB (Lubinus et al, 1994), and epidermal growth factor in a
protein kinase C-independent manner (Le Panse et al, 1996).
Psoriasis is a chronic human skin disease that affects 2–3% of the
population. It is characterized by epidermal abnormalities including
keratinocyte hyperproliferation and abnormal differentiation. It also
involves abnormal dermoepidermal microcirculation and infiltration of
the epidermis and the dermis by inflammatory cells. Psoriasis appears
to be a multigene disease (Elder et al, 1994), although its precise
etiology is unclear. On the basis of the clinical response to immuno-
modulating agents such as cyclosporin (Gottlieb et al, 1992), and the
massive T cell infiltration, psoriasis was recently described as a T cell
mediated autoimmune disease (Valdimarsson et al, 1995). Some models
of psoriatic lesions have been obtained in mice (Carroll et al, 1995;
Wrone-Smith and Nickoloff, 1996). Fibroblasts have a central role in
initiating the epidermal abnormalities observed in psoriatic lesions
(Saiag et al, 1985; Krueger and Jorgensen, 1990). Cellular and molecular
abnormalities in psoriatic skin fibroblasts include hyperproliferation
(Priestley and Adams, 1983) and increased mitogenic and chemotactic
responses to PDGF (Gu et al, 1988). In addition, the inhibitory effect
of cAMP on the proliferation of psoriatic fibroblasts is subnormal.
PKA, the intracellular mediator of cAMP, is abnormal in psoriatic cells:
both PKA activity and 8-azido-[32P]cAMP binding to the RI and RII
regulatory subunits of PKA are lower than normal in fibroblasts and
erythrocytes from psoriatic patients (Evain-Brion et al, 1986; Raynaud
et al, 1989). The abnormality is due to a post-translational alteration
affecting the regulatory subunits of PKA (Tournier et al, 1995).
Psoriatic fibroblasts are thus a unique human cell model of hyperprol-
iferation associated with abnormal PKA activity. Given the key role
of MAPK in the regulation of cell proliferation and cytoskeleton
function, and its specific negative regulation by cAMP, we investigated
MAPK in psoriatic fibroblasts and in normal fibroblasts.
MATERIALS AND METHODS
Materials Dulbecco’s modified Eagle medium (DMEM) and fetal calf serum
were from Seromed (Poly Labo Paul Block et Cie, Paris, France). Streptomycin
and penicillin were from Biological Industries (Kibbutz Beit Haemek, Israel).
PDGF AB was from Collaborative Research (Lexington, MA). 8-bromo-
cAMP, myelin basic protein (MBP), trypsin, and collagenase were from Sigma-
Aldrich Chimie SARL (Saint-Quentin Fallavier, France). [γ-32P]Adenosine
triphosphate (3000 Ci per mmole) was from Amersham (Les Ulis, France). All
other chemicals were of analytical grade.
Fibroblast culture Fibroblasts were isolated from healthy adults and untreated
psoriatic adults (psoriasis vulgaris in flare-up for µ3 mo) by enzymatic digestion
of small pieces (4 mm squares) of dermis. All the subjects were Caucasian and
the controls were matched for sex and age with the patients. This study was
approved by the ethics committee of Hoˆpital Cochin (Paris, France). To avoid
variability due to inflammation, psoriatic skin biopsies were taken from
nonlesional tissue, in which fibroflasts also bear the PKA defect (Raynaud et al,
1987). Skin fragments were rinsed twice with 5 ml of DMEM at 37°C
supplemented with 50 U penicillin per ml and 50 µg streptomycin per ml,
minced into small pieces, and incubated in 10 ml of DMEM containing 2.5 mg
trypsin per ml, 50 U penicillin per ml, and 50 µg streptomycin per ml for 1 h
at 37°C. Skin fragments were collected by centrifugation at 400 3 g for 3 min
and then incubated in 10 ml of DMEM with 1 mg collagenase per ml for 1 h
at 37°C. After centrifugation, they were incubated in DMEM containing
0.5 mg collagenase per ml for 3 h at 37°C. Isolated cells were recovered by
centrifugation at 400 3 g for 10 min, resuspended in 5 ml of DMEM containing
10% fetal calf serum, penicillin, and streptomycin, and plated in 100 mm
diameter cell culture dishes. The cells were grown in humidified 5% CO2/95%
air at 37°C and used between passages 4 and 9.
Prior to experiments, subconfluent cells were rinsed twice with 5 ml of
warm phosphate buffered saline (PBS) and incubated in 10 ml of serum-free
culture medium for 72 h. These serum-deprived cells were incubated in DMEM
containing 10% fetal calf serum or 1 ng human recombinant PDGF AB per
ml; untreated cells served as controls.
8-bromo-cAMP treatment Serum-deprived fibroblasts were incubated in
DMEM in the presence of 0.1 mM 8-bromo-cAMP for 1 h at 37°C, and fetal
calf serum was then added to a final concentration of 10% and the samples
incubated for a further 10 min.
Cell extracts Cells were washed twice with 5 ml of ice-cold PBS. They
were lyzed and scraped on ice in 50 mM β-glycerophosphate, 10 mM KH2PO4,
1 mM ethylenediamine tetraacetic acid, 5 mM ethyleneglycol-bis(β-aminoethyl
ether)-N,N,N’,N’-tetraacetic acid, 10 mM MgCl2, 1 mM sodium orthovanad-
ate, 2 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 4 mM p-
nitrophenyl phosphate, 2 µg aprotinin per ml, 0.5 µg leupeptin per ml, 1%
(vol/vol) NP-40, pH 7.4 (250 µl per dish). The cell lysate was centrifuged at
13,000 3 g for 15 min at 4°C, and the supernatant was collected and
immediately used for ion-exchange chromatography or for protein kinase assays.
Protein concentrations in the supernatants were determined by fluorometric
assay using bovine serum albumin (BSA) as standard (Bohlen et al, 1973).
Ion-exchange chromatography Cytosolic extract (10 mg) was filtered
through a 0.2 µm filter (Millipore, Saint-Quentin en Yvelines, France) and
loaded onto an anion-exchange Mono Q column (Pharmacia Biotech, Orsay,
France) equilibrated in 50 mM β-glycerophosphate, 1 mM ethyleneglycol-bis(β-
aminoethyl ether)-N,N,N’,N’-tetraacetic acid, 1 mM phenylmethylsulfonyl
fluoride, 0.2 µg aprotinin per ml, and 0.01% (vol/vol) β-mercaptoethanol,
pH 7.4 at a flow rate of 0.8 ml per min at 4°C. After a washing step with
equilibration buffer for 15 min, the sample was eluted with 25 ml of a linear
gradient (0–250 mM) of NaCl in equilibration buffer at 4°C (flow rate 1 ml
per min) (Gomez and Cohen, 1991; Trigon and Morange, 1995). Fractions of
1 ml were collected and stored at 4°C until analysis.
Antibodies and immunoblotting Anti-Erk1 sc93 was from Santa Cruz
Biotechnology, TEBU (Le Perray en Yvelines, France). Anti-rat MAP kinase
R2 was from UBI (Euromedex, Souffel Weyersheim, France). Anti-PKC was
kindly provided by Dr. W.B. Anderson (Laboratory of Cellular Oncology,
National Cancer Institute, NIH, Bethesda, MA). Anti-PKA catalytic subunit
antibody was a generous gift from Dr. S. Lohmann (Labor fu¨r Klinische
Biochemie, Medizinische Universita¨tsklinik, Wu¨rzburg, Germany).
Ten micrograms of cell extract or 1 µg of protein obtained after fast protein
liquid chromatography purification was separated on 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, and electrophoretically transferred to
0.45 µm pore size nitrocellulose membranes, in 50 mM Tris, 39 mM glycine,
20% ethanol (vol/vol), and 0.04% sodium dodecyl sulfate (vol/vol) at pH 8.5
and 23 V for 50 min. The membrane was incubated with anti-Erk1 sc93, anti-
PKA, or anti-PKC antibody (1:100), and then with a peroxidase-coupled goat
anti-rabbit antibody (1:10.000) (Amersham), and was developed using the ECL
method (Amersham). Anti-rat MAP kinase R2 was used according to the
manufacturer’s recommendations.
Protein kinase assays One microgram of protein obtained after FPLC
purification was incubated in the presence of 0.25 µCi[γ-32P]adenosine tri-
phosphate and 6 mM MBP in 20 mM HEPES (pH 7.4), 25 mM MgCl2, 40 µM
adenosine triphosphate, in a final volume of 50 µl at 30°C for 30 min. Twenty
microliters of the mixture was spotted onto 3 cm2 P81 phosphocellulose strips
(Whatman, Poly Labo Paul Block et Cie). The strips were washed four times
in ice-cold 0.5% orthophosphoric acid (10 ml per paper strip per wash) at
200 rpm (2 min each wash), dried, and counted by scintillation. Data were
corrected for values obtained with samples incubated in the absence of MBP.
To determine MAPK activity in cytosolic extracts (10 µg protein), the
reaction mixture contained 5 µM H-89 (Seikagaku, Paris, France) and 2 µM
GF 109203X (3-[1-[3- (dimethylamino)propyl]-1 H-indol-3-yl]-4 (1 H-indol-
3-yl)-1 H-pyrrole-2,5-dione monohydrochloride) (Toullec et al, 1991), a
generous gift from Dr. J. Kirilovsky (Laboratoire de Biologie, Glaxo Research
Center, Les Ulis, France). The PKA inhibitor PKI and the PKC inhibitor GF
109203X were added to the phosphorylation mixture to prevent phosphorylation
of MBP by PKA and PKC as described by Whisler et al (1995). The calcium
chelators ethyleneglycol-bis(β-aminoethyl ether)-N,N,N’,N’-tetraacetic acid
and ethylenediamine tetraacetic acid included in the lysis buffer were also
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present in the reaction mixture at 0.72 mM and 135 µM, respectively, to
inhibit the phosphorylation of MBP by Ca21/calmodulin kinases.
Confocal microscopy Cells were fixed with 4% paraformaldehyde in PBS
for 20 min at 37°C, then rinsed twice in PBS and incubated for 10 min with
PBS containing 50 mM ammonium chloride. They were then permeabilized
with 0.1% Triton X-100 in PBS containing 0.2% BSA. Incubation with an
antibody raised against a cell surface marker (N-aminopeptidase) was as
previously described.1
We used a Sarastro 2000 (Molecular Dynamics, Palo Alto, CA) confocal
microscope equipped with an argon ion laser (488–514 nm wavelength) and
mounted on either an Optiphot II Nikon microscope (360, NA, 1.40, Plan
objective) or a Zeiss Axiophot microscope (363 plan Neofluar objective).
In double-staining experiments, both fluorescein and rhodamine secondary
antibodies were used. Ten sections, each 0.25 µm thick (averaging on five full
frames of the same section) were scanned, and stacks of optical sections for
each data set were compiled by Voxel View software on a Silicon Graphics
IRIS 4D-70 GT workstation.
Flow cytometric analysis Cells were plated at 3 3 105 per 100 mm dish
in DMEM containing 10% fetal calf serum and collected 4 and 6 d later by
trypsinization. They were fixed with 4% paraformaldehyde or methanol.
Equivalent results were obtained with fixed and living cells. The sizes of normal
and psoriatic cells were compared at the same confluency (confluent or
subconfluent). Cells (25 3 104) were analyzed on a FACscan apparatus with
LYSYS II software (Becton Dickinson, Lincoln Park, NJ).
Immunocytochemistry Fibroblasts were cultured on glass slides, deprived
of serum, and then stimulated with serum or PDGF. Samples were fixed as
follows: 15, 30, 60 min, and each 3 h later until 12 h of stimulation. Fibroblasts
were washed with PBS and fixed in 60% methanol and 40% acetone at –20°C
for 8 min. After six washes with Tris-buffered saline (TBS) containing 0.1%
Tween 20 (TBST), the fixed cells were incubated with 1.5% normal goat serum
in TBST for 1 h at room temperature and then incubated with the phospho-
specific MAPK antibody (New England Biolabs, Beverly, MA) in TBS
containing 3% BSA (TBS/BSA) (1:100) for 90 min at room temperature. This
antibody binds to phosphorylated tyrosine in Erk1 and Erk2. The cells were
washed six times with TBST and incubated in TBS/BSA with biotinylated
anti-rabbit IgG antibody for 1 h (1:200; Amersham). After six washes with
TBST, cells were then incubated in TBS/BSA with Texas Red-streptavidin for
1 h (1:500; Jackson ImmunoResearch, Interchim, Asnie`res, France). After a
last washing step, cells were fixed in absolute ethanol for 1 min and covered
with mounting medium with 4,6-diamidino-2-phenylindol (Vectashield, Vector
Laboratories, Burlingame, CA). The cells were examined with a fluorescence
microscope (Olympus, Rungis, France) under epifluorescent-illumination with
excitation-emission filters for rhodamine and for 4,6-diamidino-2-phenylindol.
Incubation with biotinylated anti-rabbit IgG antibody and Texas Red-streptavi-
din alone did not reveal any significant fluorescent signal (data not shown).
Immunohistochemistry Biopsies of the buttock and abdominal skin were
obtained from psoriatic patients and from healthy control subjects. They were
quick frozen in isopentane cooled in liquid nitrogen and stored at –80°C.
Tissue sections (6 µm) were obtained with a cryostat set at –25°C and were
stored at –80°C. Sections from normal and unlesional psoriatic skin were fixed
with 60% methanol and 40% acetone at –20°C for 10 min. Tissue sections
were sequentially rehydrated with TBST and then washed five times in TBST
(2 min each wash). They were incubated with 1.5% normal goat serum in
TBST for 1 h at room temperature before incubation with the phospho-specific
MAPK antibody in TBS/BSA (1:100) overnight at 4°C. Tissue sections were
washed 10 times with TBST and incubated in TBS/BSA with biotinylated
anti-rabbit IgG antibody for 2 h (1:200). After six washes with TBST, the
samples were incubated in TBS/BSA with Texas Red-streptavidin for 1 h
(1:500). Vectashield was used to mount coverslips and sections were examined
with a fluorescence microscope as for immunocytochemistry. As controls for
specificity, tissue sections were incubated with biotinylated anti-rabbit IgG
antibody and Texas Red-streptavidin.
Disease score The severity of psoriasis affecting each patient was scored using
the Psoriasis Area and Severity Index (PASI) (Fredriksson and Pettersson, 1978).
1Gerbaud P, Keryer G, Bauvois B, Roques B, Evain-Brion D, Raynaud F:
Differential expression of two ectoenzymes in human normal and psoriatic
dermal fibroblasts. Mol Biol Cell 6:177a, 1995 (abstr.)
Figure 1. Morphologic aspect of cultured fibroblasts from normal
subjects (A, C) and psoriatic patients (B, D). (A, B) Optical microscopy;
scale bar, 20 µm. (C, D) Confocal microscopy; cells were labeled with an
antibody against a cell surface antigen (N-aminopeptidase); scale bar, 4 µm.
Statistical analysis All data are representative of at least three experiments
performed with different fibroblast cultures. Statistical significance was assessed
using by Student’s t test, with a threshold of p , 0.05.
RESULTS
Fibroblasts from psoriatic patients are larger than fibroblasts
from normal subjects As previously described (Priestley and Adams,
1983; Raynaud et al, 1991), fibroblasts from psoriatic patients were
hyperproliferative in our experimental conditions of culture. Cultured
normal and psoriatic fibroblasts were examined and found to be larger
by both standard microscopy (Fig 1A, B, respectively, for normal and
psoriatic fibroblasts) and confocal microscopy (Fig 1C, D, respectively).
Several normal and psoriatic fibroblast cultures were trypsinized and
the average cell size was measured by flow cytometry. Psoriatic
fibroblasts were significantly larger than normal fibroblasts (18.1 6 0.8 vs
14.8 6 0.9 µm; p , 0.02).
Time course of MAPK activation by serum and PDGF in
normal and psoriatic fibroblasts We studied and compared MAPK
activity in normal and psoriatic fibroblasts. The time course of the
stimulatory effect of serum (Fig 2A) and PDGF (Fig 2B), a growth
factor known to stimulate fibroblast proliferation (Gu et al, 1988), was
studied using MBP as the substrate to MAPK in the presence of PKA,
PKC, and Ca21/calmodulin kinase inhibitors. Serum and PDGF AB
treatment of serum-deprived fibroblasts led to a larger increase in
MAPK activity in psoriatic cells than in normal cells, at all time points.
Maximal activity in both normal and psoriatic fibroblasts was obtained
after 15 min of stimulation with each factor. In both normal and
psoriatic cells, MAPK activity remained elevated up to 6 h after serum
stimulation. In contrast, after 1 h of stimulation by PDGF, the MAPK
activity in normal fibroblasts was similar to that in unstimulated cells,
whereas it remained significantly elevated in psoriatic cells.
MAPK phosphorylation was visualized by gel shift assays and western
blotting with the polyclonal anti-Erk1 antibody (anti-rat MAP kinase
R2) (Fig 2D) or monoclonal or polyclonal antibodies specific for
phospho-MAPK (New England Biolabs) (data not shown). The amount
of the phosphorylated form of Erk1 and Erk2 in psoriatic fibroblast
extracts increased after PDGF stimulation, peaking after 15 min
stimulation and declining thereafter with time of stimulation to controls
(serum-deprived cell lysate) after 3 h (Fig 2D).
As normal and psoriatic fibroblasts deprived of serum for 72 h
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Figure 2. Time course of stimulation by serum or by PDGF. Subconfluent
normal and psoriatic fibroblasts were growth-arrested by 72 h of serum
depletion, and then stimulated with 10% fetal calf serum (A) or with 1 ng
PDGF per ml (B) for the periods indicated. Cells were rinsed twice with cold
PBS, and extracts were obtained as described in Materials and Methods. MAPK
activity was measured using MBP in the presence of PKA, PKC, and Ca21/
calmodulin kinase inhibitors. MAPK activity is expressed in picomoles of
inorganic phosphorus incorporated per min per mg protein. Immunoblots of
serum-deprived normal and psoriatic cell extracts (C) and immunoblots of
various cell extracts obtained during PDGF stimulation for the psoriatic
fibroblasts (D) were prepared using anti-MAPK antibody (anti-rat MAPK R2).
contained the same amounts of MAPK protein (Fig 2C), we conclude
that the difference in MAPK activity observed between normal and
psoriatic fibroblasts was not due to a difference in MAPK protein level
but to a different degree of activation.
High purified MAPK activity in psoriatic fibroblasts To deter-
mine MAPK activity more specifically, we purified these kinases from
primary cultures from five normal subjects and five psoriatic patients
by anion-exchange chromatography as described by Gomez and Cohen
(1991). We verified by immunodetection that normal and psoriatic
fibroblast extracts contained the same amount of Erks (as illustrated in
Fig 2C). MAPK was then purified from serum-deprived (– serum)
Figure 3. Characterization of Mono Q fractions by MBP
phosphorylation activity and immunoblotting. Extracts from normal (Nor)
and psoriatic (Pso) fibroblasts deprived of serum (– serum) or stimulated with
serum (1 serum) were chromatographed on Mono Q as described in Materials
and Methods, and fractions were assayed for MBP phosphorylation activity (A,
D). Results are expressed as picomoles of inorganic phosphorus incorporated
per 30 min per 10 mg protein loaded onto the column. Mono Q fractions 37–
48 were analyzed by western blotting with an anti-MAPK (B, E) or an anti-
PKC antibody (C).
Table I. Total MAPK activity in Mono Q-purified cell
extractsa
Serum-deprived Serum-stimulated PASI
fibroblasts fibroblasts score
Psoriatic fibroblasts 1 14.6 260.1 9.2
2 16.6 140.9 12.6
3 25.1 278.4 16.1
4 20.4 122 21.4
5 9.3 135.4 8.3
Mean 6 SEM 17.2 6 2.7b 187 6 33.7c
Normal fibroblasts A 9.2 121
B 9 80.9
C 6.8 61.2
D 10.8 176.9
E 9.4 114
Mean 6 SEM 9 6 1.4b 110.4 6 19.7c
aNormal and psoriatic fibroblast cytoplasmic extracts prepared from serum-deprived cells
and from serum-stimulated cells were chromatographed and analyzed in the conditions
described for Fig 3. MAPK activity was obtained by summing the MBP phosphorylation
activity of the fractions containing Erk1 and Erk2 immunoreactivity. Results are expressed
as picomoles of inorganic phosphorus incorporated per 30 min per 10 mg protein loaded
onto the column.
bSerum-deprived psoriatic fibroblasts versus normal fibroblasts; p , 0.01.
cSerum-stimulated psoriatic fibroblasts versus normal fibroblasts; p , 0.05.
and serum-stimulated (1 serum) extracts of normal and psoriatic
fibroblasts (Fig 3). MBP kinase activity was measured in the anion-
exchange chromatography fractions (FPLC) (Fig 3A, D). The activity
was assayed in the presence of phosphatase inhibitors and in the absence
of kinase inhibitors. The activity was detected in fractions 41–45
(NaCl concentrations between 160 and 200 mM) for serum-deprived
fibroblasts (Fig 3A) and in fractions 41–47 for stimulated fibroblasts
(Fig 3D). As shown in Figs 3A and 3D, MAPK activity was higher
in the psoriatic cell extracts than in normal cells. The total MAPK
activity was estimated by summing MAPK activity of the fractions.
The mean activity in normal serum-deprived fibroblasts (9 6 1.4
picomoles per 30 min per 10 mg protein loaded onto the column)
was significantly lower than that in serum-deprived psoriatic cells
(17.2 6 2.7; p , 0.01) (Table I). Similarly, for serum-stimulated
cultures, the mean MAPK activity in psoriatic cultures (187 6 33.7
picomoles per 30 min per 10 mg protein loaded onto the column)
was significantly higher than that in normal cultures (110.4 6 19.7;
p , 0.05) (Table I). Furthermore, the MAPK activity in serum-
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deprived psoriatic fibroblast extracts correlated (R2 5 0.6) with the
severity of cutaneous manifestations (PASI score).
FPLC fractions were analyzed by immunoblotting using anti-Erk1/
Erk2 antibody. Erks were immunodetected in fractions 39–47 in
serum-deprived fibroblasts (Fig 3B) and in fractions 41–47 in serum-
stimulated fibroblasts (Fig 3E). We confirmed that the phosphorylated
active forms of Erks were eluted after the inactive forms as demonstrated
by Gomez and Cohen (1991). As assessed by mobility shift of Erk1
on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the
phosphorylated form of Erk1 was immunodetected in fractions 41–44
in serum-deprived fibroblasts (Fig 3B) and in fractions 42–47 in serum-
stimulated fibroblasts (Fig 3E).
MBP is a substrate for several kinases including PKA, PKC, and
Ca21/calmodulin kinases. In our experimental conditions (see Materials
and Methods), Ca21/calmodulin kinases were always inhibited. We
checked by immunoblot analysis with antibodies against PKA and
PKC that the PKA catalytic subunit eluted in the flow through (data
not shown) and PKC was immunodetected in fractions 38, 39, and
40 (NaCl concentrations between 130 mM and 150 mM) (Fig 3C).
8-bromo-cAMP inhibits MAPK phosphorylation in normal but
not in psoriatic serum-stimulated fibroblasts PKA may indirectly
regulate MAPK via Raf (Wu et al, 1993; Hafner et al, 1994) and
psoriatic fibroblasts present a PKA abnormality (Raynaud et al, 1989).
The stimulatory effect of serum on MAPK phosphorylation was
therefore compared in normal and psoriatic fibroblasts incubated in
the presence or absence of 8-bromo-cAMP. The Erk pattern was
studied by immunoblotting with an anti-MAPK antibody (Fig 4A).
In normal and psoriatic fibroblasts treated with serum, three bands
were detected; the two major bands corresponded to the activated
phosphorylated forms of Erk1 and Erk2, and the minor band to
nonphosphorylated Erk1. In psoriatic cells, preincubation with 8-
bromo-cAMP did not modify the Erk pattern. In contrast, in normal
cells, incubation with 8-bromo-cAMP increased the amount of non-
phosphorylated Erk1 and resulted in the presence of a fourth band.
Using a serum-deprived fibroblast lysate, we demonstrated that this
additional fourth band corresponded to the nonphosphorylated form
of Erk2. Scanning the immunoblots for normal fibroblast lysates
revealed a diminution of phosphorylated forms of Erk1 and Erk2 after
pretreatment with 8-bromo-cAMP (Fig 4B) and an increase in the
amount of nonphosphorylated forms. For psoriatic fibroblast extracts,
8-bromo-cAMP pretreatment did not provoke any significant change
in Erk pattern (Fig 4C). 8-bromo-cAMP pretreatment inhibited
serum-stimulated MAPK activity by around 30% and 3%, respectively,
in normal and psoriatic fibroblast extracts.
Variation in nuclear localization of phosphorylated
MAPK Activated MAPK translocate into the nucleus (Chen et al,
1992; Lenormand et al, 1993). We followed the effect of either serum
or PDGF AB stimulation on the translocation of MAPK into the
nucleus by immunofluorescence microscopy using an antibody specific
for the phosphorylated forms of Erk1 and Erk2 (Figs 5 and 6). After
72 h serum depletion, no or very few normal (Figs 5A and 6A) or
psoriatic (Figs 5B and 6B) cells showed cytoplasmic staining. Perin-
uclear staining of phosphorylated MAPK was observed in both psoriatic
and normal fibroblasts. There was no significant difference in the
immunostaining profile (intensity or number of stained cells) between
normal and psoriatic serum-deprived fibroblasts. After a short stimula-
tion with serum (15 min or 30 min), we observed an increase in
phosphorylated Erks in the cytoplasm surrounding the nucleus in both
normal cells and psoriatic fibroblasts (data not shown). After 1 h of
serum stimulation, phosphorylated Erks were detected in the nuclei of
the majority of normal fibroblasts (Fig 5C), whereas no nuclear staining
was visible in the psoriatic fibroblasts (Fig 5D). After 3 h serum
stimulation, most phosphorylated Erk staining was observed inside the
nuclei in normal fibroblasts as well as in psoriatic fibroblasts (Fig 5E,
F). During the studied time frame, no phosphorylated MAPK was
observed in the nuclei of psoriatic fibroblasts before 3 h of serum
stimulation in three independent experiments. The phosphorylated
Erks were cytoplasmic in normal and psoriatic fibroblasts after 6 h of
serum stimulation (data not shown).
Figure 4. Effect of 8-bromo-cAMP on MAPK phosphorylation.
Subconfluent normal (Nor) and psoriatic (Pso) fibroblasts were stimulated with
10% fetal calf serum for 10 min with or without pretreatment with 100 µM
8-bromo-cAMP for 1 h. (A) Cytosol extracts (10 µg protein) were analyzed
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
immunoblotted with an anti-MAPK antibody (anti-rat MAPK R2). Scanning
densitometry values (means 6 SEM) of phosphorylated and unphosphorylated
Erk1 and Erk2 bands are reported for normal (B) and psoriatic (C) fibroblast
extracts (n 5 3).
The findings for PDGF stimulation were dissimilar to those for
serum stimulation. Phosphorylated forms of Erks were apparent in the
nuclei of psoriatic fibroblasts within 30 min and after 1 h and 3 h of
PDGF stimulation (Fig 6D, F, H). In normal cells, phosphorylated
Erks were observed in the nucleus only after 1 h of PDGF stimulation
(Fig 6E), and were in the cytoplasm surrounding the nucleus after
30 min and 3 h of PDGF stimulation (Fig 6C, G).
We investigated the subcellular localization of phosphorylated Erks
in skin samples from healthy (Fig 7A) and psoriatic (Fig 7B) subjects
by immunostaining with the antibody recognizing the phosphorylated
forms of Erk1 and Erk2 (three normal and four psoriatic skins were
analyzed). Nuclear phosphorylated Erks appeared as bright dots in the
nuclei of cells. The nuclear localization was confirmed by DAPI
staining. Nuclear staining was observed in keratinocytes and in dermal
cells in both normal and psoriatic skin samples. We observed no
significant difference in the staining pattern with the phospho-specific
Erk antibody between normal and nonlesional psoriatic skins.
DISCUSSION
Dermal fibroblasts may play a primary role in psoriasis (Priestley, 1991),
and psoriatic fibroblasts are hyperproliferative. Here, we found that
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Figure 5. Immunolocalization of phosphorylated Erk1 and Erk2 after
serum stimulation. Normal (A, C, E) and psoriatic (B, D, F) fibroblasts were
cultured on glass slides and then subject to serum depletion for 72 h. Cells
were not treated (A, B) or were stimulated with serum for 1 h (C, D) or for
3 h (E, F) and fixed in 60% methanol and 40% acetone at –20°C. They were
incubated with the phospho-specific MAPK antibody, then with a biotinylated
anti-rabbit IgG antibody and finally with Texas Red-streptavidin. The samples
were examined with a fluorescence microscope under epifluorescent illumination
with excitation-emission filters for rhodamine; scale bar, 10 µm.
psoriatic fibroblasts in culture were significantly larger than normal
fibroblasts. Psoriatic fibroblasts display a PKA abnormality (Raynaud
et al, 1989) and we show that they also have high MAPK activity.
We found significantly and reproducibly higher MAPK activity in
serum-deprived fibroblasts and in serum- or PDGF-stimulated
fibroblasts from psoriatic patients than in fibroblasts from normal
subjects. This higher activity was evidenced by MAPK purification from
cell extracts by anion-exchange chromatography. The chromatographic
Figure 6. Immunolocalization of phosphorylated Erk1 and Erk2 after
PDGF stimulation. After 72 h of serum depletion, normal (A, C, E, G) and
psoriatic (B, D, F, H) fibroblasts were not treated (A, B) or were stimulated
with PDGF for 30 min (C, D), for 1 h (E, F), or for 3 h (G, H).
Immunocytochemistry was as described for Fig 3; scale bar, 10 µm.
behavior of MAPK in normal and psoriatic cell extracts was identical
in our experimental conditions, and was consistent with previous
reports (Gomez and Cohen, 1991; Trigon and Morange, 1995). A
recent study showed an increased MAPK activity associated with an
increased protein level in human breast cancer cells (Sivaraman et al,
1997). In our study, MAPK activity was higher in psoriatic fibroblasts
than in normal cells but the amounts of MAPK protein level were
the same.
The high MAPK activity in psoriatic fibroblasts may have been due
to low phosphatase activity, as phosphatases inhibit these kinases. Most
dual-specificity phosphatases are immediate-early mitogen inducible
phosphatases (Zolnierowicz and Hemmings, 1996). Thus, a diminished
activity of these phosphatases would not explain the increase in MAPK
activity observed in serum-deprived psoriatic fibroblasts; however,
Pyst1, a MAPK dual specificity phosphatase, is expressed constitutively
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Figure 7. Immunohistochemical analysis of human skin. Thin sections
(6 µm) of either normal skin (A) or nonlesional psoriatic skin (B) fixed at –
20°C in 60% methanol and 40% acetone were examined by fluorescence
microscopy following staining with the phospho-specific MAPK antibody.
White arrows indicate positive staining in nucleus of epidermic and dermic
cells; scale bar, 50 µm.
in human skin fibroblasts (Groom et al, 1996). The high MAPK activity
in psoriatic fibroblasts may thus be due to low Pyst1 activity.
The PKA can indirectly regulate Erks via Raf in several cell types.
Raf phosphorylation by PKA might either prevent Raf kinase activation
(Hafner et al, 1994) or inhibit Ras/Raf interaction (Wu et al, 1993).
The altered PKA activity in psoriatic fibroblasts is associated with
decrease of cAMP binding to regulatory subunits (Evain-Brion et al,
1986; Raynaud et al, 1989). Therefore, using our primary culture
model, we checked that an increase in intracellular cAMP inhibited
serum-induced activation of MAPK in normal dermal fibroblasts, as
described in transformed cells by Hordijk et al (1994). Our results
support the negative regulation of the MAPK pathway by PKA in
these cells. Interestingly, we found that 8-bromo-cAMP treatment of
psoriatic fibroblasts had virtually no inhibitory effect on serum-activated
MAPK and did not modify the pattern of phosphorylated (activated)
Erks. In contrast, 8-bromo-cAMP treatment of serum-stimulated
normal fibroblasts increased the levels of nonphosphorylated (not
activated) Erk1 and Erk2. Therefore, in psoriatic fibroblasts the low
cAMP-stimulated PKA activity is associated with a lesser capacity of
this enzyme to inhibit MAPK indirectly via Raf.
Serum-deprived fibroblasts from normal subjects show higher
intracellular cAMP concentrations (Boynton and Whietfield, 1983),
higher activated PKA, and therefore lower MAPK activity. Serum
deprivation caused a similar increase in cAMP levels in psoriatic
fibroblasts, but the PKA activation was weak (F. Raynaud, unpublished
data). Thus there is no evidence for having a PKA inhibitory effect
on the MAPK pathway via Raf in psoriatic fibroblasts. Culture in
serum-free medium may amplify the difference in MAPK activity
between normal and psoriatic fibroblasts. This would explain why the
increase in MAPK activity observed in psoriatic fibroblasts was more
significant for serum-deprived fibroblasts than for serum-stimulated
cells. In addition, serum-free culture conditions may be the most
appropriate for the comparative study of MAPK in normal and psoriatic
fibroblasts. Indeed, MAPK is not only involved in the G0/G1 transition,
but also has two phases of activation during the cell cycle: during the
G1 and G2/M phases (Tamemoto et al, 1992). A recent study confirmed
the hyperproliferative state of psoriatic fibroblasts and revealed signific-
antly longer S and G2/M phases in psoriatic fibroblast cultures than in
normal cells (Espinoza et al, 1994). Therefore, studies of MAPK in
nonsynchronized serum-stimulated cells are difficult to interpret. In
our experiments, after 72 h of serum deprivation, 90% of both normal
and psoriatic fibroblasts were in the G0/G1 phase (FACscan analysis,
data not shown).
The size of psoriatic fibroblasts in culture may be due to a modified
expression of proto-oncogenes such as c-myc and c-fos (Basset-Seguin
et al, 1991), which are MAPK substrates (Pelech and Sanghera, 1992;
Gille et al, 1995). The high nuclear MAPK activity may thus be
responsible for the ability of psoriatic cells to hyperproliferate, as well
as for the abnormalities in cell size and shape. As MAPK, like PKA,
interacts with microtubules (Reszka et al, 1995) and other cytoskeleton
proteins (Han and Rubin, 1996), the cytoskeletal abnormalities in
psoriatic cells may be due to the modified MAPK activity.
Interestingly, the kinetics of MAPK activation by serum or by PDGF
were not the same in normal and psoriatic fibroblasts: the effects were
larger and more durable in psoriatic cells. We investigated whether
this phenomenon was associated with an abnormal MAPK subcellular
localization. We reproducibly detected small amounts of phosphorylated
Erks in the cytoplasm of normal and psoriatic serum-deprived
fibroblasts. We did not observe any nuclear translocation of Erks after
brief serum-stimulation as described by Lenormand et al (1993) in
transformed Chinese hamster lung fibroblasts. The different time course
obtained might be due to the use of a transformed cell line (CCL39)
in the previous study and fibroblast primary cell cultures in ours. In
addition, the localization of phosphorylated forms of MAPK was
different in normal and psoriatic fibroblasts: phosphorylated active Erks
were nuclear after 30 min, 1 h, and 3 h of PDGF stimulation in
psoriatic fibroblasts, but were found in the nuclei of normal fibroblasts
only after 1 h of PDGF stimulation. The translocation of phosphorylated
and active MAPK in stimulated PDGF psoriatic fibroblasts is more
rapid and more sustained than in normal cells. Therefore the mitogenic
and chemotactic effects of PDGF are larger in psoriatic fibroblasts that
present an increased number of PDGF receptors than in normal cells
(Krane et al, 1991). In contrast, serum-stimulated MAPK translocated
into the nuclei of psoriatic fibroblasts later than in normal cells. The
nuclear translocation in psoriatic fibroblasts was transient, phosphoryl-
ated MAPK staying in the nuclei less than 1 h. These observations are
consistent with the previous demonstration that the nuclear transloca-
tion of MAPK is independent of their phosphorylation and their
phosphotransferase activity (Lenormand et al, 1993). The mechanism
of MAPK translocation into the nucleus remains unclear, and no
nuclear localization sequence can be identified in MAPK. Unlike
PDGF, serum contains numerous factors including growth factors and
proteases. After serum stimulation of psoriatic fibroblasts, one or more
of these factors may delay the translocation of phosphorylated MAPK
into the nuclei.
No difference between normal and nonlesional psoriatic skins
was observed by immunohistochemistry with an antibody against
phosphorylated MAPK. Some cells in the epidermis and the dermis of
both skins presented a nuclear immunostaining. The discrepancy
between this result and the immunocytochemical findings could be
associated with the cells in skin being in different stages of the cell
cycle. We also failed to find any difference in nonsynchronized normal
and psoriatic fibroblasts in culture.
In conclusion, we found that MAPK activity was higher in cultured
psoriatic fibroblasts than in normal fibroblasts. This is the first example
of a MAPK pathway abnormality in a human benign hyperproliferative
disease. An abnormality of PKA might induce alteration in another
major signal transduction pathway due to the close interrelationships
between the different cell signal transductions. Elucidation of the
mechanisms by which elevated activated MAPK alters cell functions
may help to explain the pathogenesis of psoriasis.
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